# Exhibit 364

United States of America ex rel. Ven-A-Care of the Florida Keys, Inc., et al. v. Dey, Inc., et al., Civil Action No. 05-11084-PBS

Exhibit to the August 28, 2009 Declaration of Sarah L. Reid in Support of Dey's Opposition to Plaintiffs' Motion for Partial Summary Judgment

#### Charlotte, NC

November 11, 2008

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS Civil Action No. 01-12257-PBS In re: PHARMACEUTICAL INDUSTRY : AVERAGE WHOLESALE PRICE : LITIGATION : MDL No. 1456 THIS DOCUMENT RELATES TO: : Unites States of America ex : rel. Ven-a-Care of the Florida : Keys, Inc., et al. v. Dey, : Inc., et al., Civil Action : No. 05-11084-PBS (Cross captions appear on the following pages) Video deposition of WILLIAM HILL, taken by the United States of America, at 2800 Coliseum Center Drive, Charlotte, North Carolina, on the 11th day of November, 2008 at 9:02 a.m., before Andrea L.

Henderson Legal Services, Inc.

Nobrega, Court Reporter and Notary Public.

202-220-4158

# Charlotte, NC

November 11, 2008

104

- party customer, you are not really talking about
- a customer of Dey, rather you are talking about a
- third-party payer who would pay for the product
- 4 that was purchased by a patient or a health -- or
- 5 a doctor, for example?
- 6 A. Correct.
- Q. Was it your understanding then that a
- 8 pricing objective of Dey was to provide incentive
- 9 to retail and chain providers to use Dey's
- 10 Cromolyn by increasing the spread on third-party
- payer reimbursements?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: Again, I don't think it
- was promoted to us as increase of spread. I
- think it was to provide a cost effective, safe,
- 16 generic alternative that benefited the pharmacy
- <sup>17</sup> and the patient.
- 18 BY MR. HENDERSON:
- Q. If Dey's AWP was significantly higher
- than its actual sales price, and therefore, the
- 21 acquisition cost paid for by the retail or chain
- 22 pharmacist, would in your experience that result

## Charlotte, NC

November 11, 2008

128

- 1 Did you mean to say yes?
- THE WITNESS: I'm sorry, it's another
- way, semantics to say we are trying to
- 4 incorporate these products together as opposed to
- being, you know, one product at a time evaluated.
- 6 BY MR. HENDERSON:
- Q. And these two bullets, the third one
- and the fifth one, which are similar, although I
- <sup>9</sup> think you said they were somewhat difficult to
- implement, nonetheless, were they objectives that
- you attempted to implement in a general sense?
- 12 A. In a general sense we did try to have
- those discussions to broaden the Dey
- 14 representation with customers, but as I said, it
- was very quickly dismissed.
- Q. The fourth objective, which we
- discussed, did you also have as an objective in
- your sales calls to encourage the use of Dey's
- 19 Cromolyn by pointing out the spread on third-
- 20 party reimbursements?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: Again, I don't think that

## Charlotte, NC

November 11, 2008

129

- would be an accurate characterization. I think,
- again, we were selling a plastic vial product
- versus a brand product that was made in glass.
- 4 So we had far different issues with mothers
- 5 snapping open the top of a glass ampule and
- getting glass splinters in their finger and
- 7 having bloody fingers.
- 8 So the packaging in Cromolyn was even a
- bigger sell than the price point, because at that
- point mothers really didn't care. They were just
- tired of getting bloody fingers from snapping the
- tops off of glass ampules.
- So again, that was probably a three or
- 14 four prong strategy with the packaging, the right
- product at appropriate market pricing, and
- <sup>16</sup> affording patient opportunity to save some money,
- <sup>17</sup> too.
- 18 BY MR. HENDERSON:
- Q. So is it your testimony that a spread
- was not something that you discussed in promoting
- 21 Dey's Cromolyn sodium products?
- MS. GIULIANA: Objection to the form.

## Charlotte, NC

November 11, 2008

131

- A. Another factor at this point in time,
- too, is an inventory holding cost for a customer.
- 3 A customer would much rather have less capital
- 4 tied up on a less expensive drug on a shelf as
- opposed to more money tied up in a more expensive
- 6 brand product. That was a selling point in
- <sup>7</sup> promoting generics over brands, so the working
- 8 capital issue for a pharmacy.
- <sup>9</sup> Q. Meaning because the generic was less
- expensive, you would have less money tied up with
- product on a shelf?
- A. That's correct.
- MR. HENDERSON: I would like to have
- this marked as Exhibit No. 6.
- 15 (Exhibit Hill 006 marked for
- identification.)
- MR. HENDERSON: I'm sorry, your copies
- 18 are two-sided.
- 19 If you could look through this
- 20 document, sir, I would appreciate it.
- MS. GIULIANA: I think it's -- never
- 22 mind.

Henderson Legal Services, Inc.

202-220-4158

## Charlotte, NC

November 11, 2008

143

- person that was smaller, the multidose allowed
- doctors to titrate doses, whereas Dey's was a
- 3 standardized dose.
- So I think the message for Dey was --
- the selling message was, this is not to replace
- 6 20 ml, but where appropriate, where it's a
- <sup>7</sup> standard dose here and a standard dose here, one
- of the selling messages was if your grandmother
- 9 had asthma and was 85 years old, would you trust
- her to use a dropper -- it was about that big --
- to put it into a nebulizer and then get some
- saline to mix her own -- basically to mix her own
- dose of medication or would you prefer to have an
- 14 alternative where it's a safe infection limiting
- option for her.
- Q. When you received some instruction from
- Debi Codute, did you cover -- did you cover how
- 18 to educate pharmacists on the different
- reimbursements of Dey's product as compared to a
- 20 competitor's product?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: I wouldn't say

Henderson Legal Services, Inc.

202-220-4158

#### Charlotte, NC

November 11, 2008

144

- reimbursements plural. I would say here is a
- unit, a potential unit dose scenario and here is
- what we understand to be today's multidose plus
- 4 saline scenario.
- 5 BY MR. HENDERSON:
- 6 Q. So it did include comparing the
- 7 reimbursement on Dey's unit dose product as
- 8 compared to a competitor's multidose product?
- <sup>9</sup> A. Yes, it did.
- Q. Was that comparison for the purpose of
- educating the pharmacist on the fact that the
- pharmacist could make more profit by selling
- Dey's unit dose product as compared to selling a
- competitor's multidose product?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: In theory, yes.
- MR. HENDERSON: I would like to have
- this next document marked as Exhibit No. 7.
- 19 (Exhibit Hill 007 marked for
- identification.)
- BY MR. HENDERSON:
- Q. Mr. Hill, I have handed you a document

Henderson Legal Services, Inc.

202-220-4158

#### Charlotte, NC

November 11, 2008

156

- of it?
- A. Which, in fact, was the same product
- with a different NDC number, which would have by
- default had to have a different AWP than what you
- see on these to be characterized as a generic.
- 6 Q. And the Arcola product, which was a
- 7 generic was to your recollection priced lower
- than Dey's product?
- 9 A. That's why Dey had to adjust, one of
- the reasons why they had to adjust the price.
- Q. And coming back to Exhibit No. 8, is it
- your recollection that when Dey's price went
- down, the spread or profit as I think you
- referred to it, increased for purchasers of Dey's
- 15 Cromolyn?
- A. I think it -- to be clear, it put Dey
- at parity with the competition in the
- marketplace. There was not -- Dey didn't go
- below competitive prices. They matched
- 20 competitive prices in the market.
- Q. Do you know whether or not the amount
- of profit for Dey's Cromolyn was greater or less

#### Charlotte, NC

November 11, 2008

162

- Q. Do you recall the subject matter of the
- group one workshop here, multidose study-
- 3 hospital?
- A. That was -- as I referenced earlier, at
- this point in time there was a lot of concern
- about infection and the joint commission for the
- 7 accreditation of hospitals.
- The acronym JCAOH that I referred to
- earlier, there was a lot of issues with patient
- safety and infection in hospitals, so the
- 11 multidose -- there was a standard dose in a
- 12 hospital setting.
- The focus of that was to talk about the
- impact and potential liabilities that the
- hospitals had from this joint commission in using
- not just a multidose product, but any products
- where there is risk of infection to patients.
- Q. Did that involve information to help
- sales reps better promote the unit dose Albuterol
- 20 product that Dey sold?
- <sup>21</sup> A. Yes.
- Q. Turning to the group two topic --

#### Charlotte, NC

November 11, 2008

163

- actually, let me withdraw that comment. I'm
- going to hand you what's been marked as Hill
- 3 Exhibit No. 10.
- If you are looking at this landscape
- fashion, in the lower right-hand corner of this
- indicates the theme building on success. Do you
- 7 see that?
- <sup>8</sup> A. Yes.
- 9 Q. Can you tell us whether or not this was
- material that was used at the 1995 national sales
- 11 meeting in Arizona?
- A. Yes, I would think that it was.
- Q. Was this handed out at the group two
- workshop?
- A. Yes, I think it would have been.
- Q. And does this describe in part what was
- discussed during that group two workshop?
- <sup>18</sup> A. Yes.
- Q. Do you have an understanding as to
- whether or not these materials were made
- 21 available to all of the sales reps who attended
- that workshop?

## Charlotte, NC

November 11, 2008

164

- MS. GIULIANA: Objection to the form.
- THE WITNESS: All I can speak is what I
- 3 saw in my group, is that everybody would have
- 4 received the same materials.
- 5 BY MR. HENDERSON:
- Q. So if they follow the same approach for
- <sup>7</sup> the other groups, they would have received these
- 8 materials as well?
- 9 MS. GIULIANA: Objection to the form.
- THE WITNESS: I guess you could assume
- 11 that, yes.
- 12 BY MR. HENDERSON:
- Q. During that workshop, was there
- discussion about AWP reimbursement, why it's
- important, how it's calculated and what it means
- in terms of reimbursement from the third-party
- payers to the managed care organizations?
- A. Yes, there was.
- Q. And of course I read from the bullets
- on the first page of Exhibit No. 10.
- Was there also discussion at the
- workshop about why multidose to unit dose

Henderson Legal Services, Inc.

202-220-4158

#### Charlotte, NC

November 11, 2008

165

- 1 Albuterol conversion makes good business sense
- for the customer base?
- <sup>3</sup> A. Yes.
- Q. And what do you recall about why
- 5 converting from multidose to unit dose Albuterol
- 6 would make good business sense for the customer?
- A. Well, based on some assumptions that
- were gathered in the field in a couple different
- 9 markets -- specifically I guess that Debi Codute
- had done the majority of their research in this
- 11 area with unit test and multidose.
- 12 It was her conclusion that there would
- be opportunity both for a profit alternative for
- a pharmacy and then also the other things we
- talked about earlier with product safety and lack
- of infection risk.
- Q. Okay. So there was two basic factors.
- One was the quality of the Dey product and its
- 19 safety advantages, that was one?
- A. Uh-huh.
- Q. And the other factor was a pharmacist
- 22 could make more profit using the multi -- I'm

Henderson Legal Services, Inc.

202-220-4158

# Charlotte, NC

November 11, 2008

173

- MS. GIULIANA: Objection to the form.
- THE WITNESS: Actually I could point
- out to you on page one where there is a flaw that
- we found out after the fact with the assumptions
- on the multidose. If you look on line three that
- it says zero for reimbursement for saline?
- 7 BY MR. HENDERSON:
- O. Yes.
- <sup>9</sup> A. Actually, and you will probably see, I
- 10 know they are not in the call reports, but for
- patients to use this, it was a multidose
- concentrate where you needed to add saline to it.
- So, in fact, a lot of the plans did
- cover at a disproportionately high amount, they
- 15 did pay for saline.
- So the flaw is when we run out and use
- this in the field and showed this to pharmacies,
- and they said, okay, yeah, they understood the
- 19 concept here, and then they would put in their
- own numbers, actually some disproportionately
- high reimbursements were being paid for water,
- 22 saline.

#### Charlotte, NC

November 11, 2008

174

- So the impact of -- in a lot of cases I
- agree with you, that the Dey product was still
- more profitable, but the fact that there was a
- <sup>4</sup> zero in here -- in the sales meeting there always
- was a zero. Nobody knew that any third parties
- 6 would pay for more, but it stands to reason to
- <sup>7</sup> appropriately dose a product, you needed, number
- one, to add the saline to dilute it to the right
- 9 concentration, and number two, you need to use a
- saline to rinse it out because you didn't want
- the infection in your -- risk in your nebulizer.
- Q. So you later learned that for
- multidosed products that at least some third-
- party payers did reimburse for saline?
- <sup>15</sup> A. Right.
- Q. Is it fair to say that whoever authored
- this didn't realize that?
- A. I think they may have missed that
- 19 detail, yes.
- Q. And you would agree that even with the
- 21 correcting for that error, the profit per patient
- 22 per year for the Dey Albuterol product was

## Charlotte, NC

November 11, 2008

175

- 1 greater than for the multidose competitive
- product?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: Actually, believe it or
- not, there were cases in Philadelphia where we
- for the ran the model that plans paid so much for the
- saline, that actually a multidose was more
- 9 profitable than the unit dose.
- 9 It completely shot holes -- in certain
- 10 cases -- now there are certain cases it's not a
- one size fits all. There were certain cases
- where Dey was more profitable to unit dose, but
- there were other cases to use a multidose plus a
- saline was a more profitable option for a retail
- 15 pharmacist.
- 16 BY MR. HENDERSON:
- Q. And these situations where the
- 18 multidose was more profitable, was -- were those
- a minority or majority of situations? What's
- your recollection about that?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: It would be hard to say

Henderson Legal Services, Inc.

202-220-4158

## Charlotte, NC

November 11, 2008

179

- multidose product. Do you recall that question
- <sup>2</sup> and answer?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: (Witness nods head.)
- 5 BY MR. HENDERSON:
- Q. Do you recall whether or not this sort
- of worksheet that is Exhibit No. 12 or the two
- 8 worksheets that are part of -- that are Exhibit
- 9 No. 11, were used at that time or that you saw
- such things at that time in 1994?
- MS. GIULIANA: Objection to the form.
- THE WITNESS: I don't recall a specific
- sheet. I do remember sitting with Debi with a
- legal pad and her showing me, just handwriting
- some things out and explaining this is how this
- scenario might work and different situations, a
- generic versus a brand, this is how it might play
- <sup>18</sup> out.
- I don't remember a formal structure,
- but I know that it was part of Debi's overall
- daily sales planning her presentation prior to
- the national sales meeting in February '95.

#### Charlotte, NC

November 11, 2008

237

- unit dose conversion" reprint and worksheet and
- the "retail profit gain" worksheet. You used
- both successfully last year. Re-familiarize
- 4 yourselves with these two pieces so they can work
- 5 to your advantage again.
- These pieces should reinforce the
- <sup>7</sup> importance of our unit dose business and also
- 8 help you strategize where to pick up multidose
- business. Let us not forget that unit dose
- should remain our top priority. Did I read that
- 11 correctly?
- A. Yes, that's correct.
- Q. Was it your understanding that the
- sales of Dey's unit dose product was still a top
- priority when Dey launched its multidose product?
- <sup>16</sup> A. Yes.
- Q. Did you understand that Dey -- it was
- Dey's policy that sales reps continue to use the
- reimbursement comparison worksheet in order to
- 20 convert customers from using a multidose
- 21 competitor product to Dey's unit dose product at
- least where it seemed appropriate in the

Henderson Legal Services, Inc.

202-220-4158

## Charlotte, NC

November 11, 2008

287

- MR. HENDERSON: I have no further
- questions. Thank you, sir.
- MS. HANSCOM: On behalf of California,
- 4 I will just have to reserve my time. I haven't
- 5 had sufficient time in order to allow Ms.
- 6 Giuliana time to cross.
- MS. ROGERS: On behalf of the State of
- Florida, we would reserve as well.
- 9 MR. AZORSKY: On behalf of Ven-A-Care
- of the Florida Keys, we reserve time to ask
- questions as well in order to give Ms. Giuliana
- 12 15 minutes to ask her questions.
- MR. WINGET-HERNANDEZ: On behalf of my
- 14 client, I reserve my questions as well.

15

- EXAMINATION BY COUNSEL FOR DEY, INC.
- AND DEY, L.P.
- 18 BY MS. GIULIANA:
- Q. Mr. Hill, you worked for Dey from April
- <sup>20</sup> 1994 to August of 1996, correct?
- A. Correct.
- Q. And during that time you were an

# Charlotte, NC

November 11, 2008

288

- outside sales rep for Dey, correct?
- A. Correct.
- Q. And you called on Dey's local customers
- 4 in Pennsylvania?
- 5 A. That's correct.
- Q. You didn't call on national customers,
- 7 correct?
- 8 A. No, did not.
- Q. And no one reported to you?
- 10 A. No.
- Q. What was your territory again?
- 12 A. Exclusive to the State of Pennsylvania.
- Q. So all of the testimony that you gave
- today with respect to your communications with
- 15 customers is confined to the Pennsylvania
- 16 territory?
- MS. HANSCOM: Object to the form.
- MS. GIULIANA: You can answer.
- THE WITNESS: Yes.
- 20 BY MS. GIULIANA:
- Q. So you never made a call on a customer
- in California, correct?

Henderson Legal Services, Inc.

202-220-4158

# Charlotte, NC

	289
1	MS. HANSCOM: Object to the form.
2	THE WITNESS: I did not.
3	BY MS. GIULIANA:
4	Q. Nor did you make any calls on customers
5	in Florida, correct?
6	MR. AZORSKY: Objection to the form.
7	MR. HERNANDEZ: Objection, leading.
8	MS. HANSCOM: Objection to the form.
9	THE WITNESS: I did not.
10	MS. HANSCOM: Ms. Giuliana, just so we
11	don't have all of us objecting.
12	MS. GIULIANA: Objection for one is
13	good for all.
14	BY MS. GIULIANA:
15	Q. Did you make any calls on customers in
16	New York
17	MS. HANSCOM: Object to the form.
18	THE WITNESS: No.
19	BY MS. GIULIANA:
20	Q. Did you make any calls on customers in
21	Wisconsin?
22	MS. HANSCOM: Object to the form.

#### November 11, 2008

#### Charlotte, NC

290 1 THE WITNESS: No. 2 BY MS. GIULIANA: 3 And you testified a lot today about Ο. call reports that you created in the course of 5 your work at Dey, correct? 6 MS. HANSCOM: Object to the form. 7 THE WITNESS: Yes. 8 BY MS. GIULIANA: 9 Did call reports play any role in a Ο. 10 customer placing an order with Dey? 11 MS. HANSCOM: Object to the form. 12 THE WITNESS: Not necessarily. 13 BY MS. GIULIANA: 14 Q. Did you get paid off of the call 15 reports that you submitted to Dey? 16 MS. HANSCOM: Object to the form. 17 THE WITNESS: No, I did not. 18 BY MS. GIULIANA: 19 Q. Were your commissions at Dey based on 20 the call reports that you submitted? 21 MS. HANSCOM: Object to the form. 22 THE WITNESS: No, they were not.

November 11, 2008

#### Charlotte, NC

297 MS. HANSCOM: Object to the form. THE WITNESS: I did not. 3 BY MS. GIULIANA: Isn't it correct that you worked for Ο. several pharmaceutical companies before you 6 started working at Dey in 1994? Α. I did. Approximately how many years have you ο. 9 been in the drug business prior to Dey? 10 Α. Approximately eight years. 11 Is the spread a concept that you heard Q. 12 about before you started working at Dey? 13 Α. It is. 14 MS. HANSCOM: Object to the form. 15 BY MS. GIULIANA: 16 Is the spread something that Dey 0. 17 invented? 18 MS. HANSCOM: Objection to the form. 19 THE WITNESS: No. 20 BY MS. GIULIANA: 21 Is the spread something that is unique Q. 22 to Dey?

Henderson Legal Services, Inc.

202-220-4158

## Charlotte, NC

November 11, 2008

298 MS. HANSCOM: Object to the form. MS. GIULIANA: You can answer. THE WITNESS: Not at that point in time, no. BY MS. GIULIANA: Is the spread something that Dey taught Q. you about? MS. HANSCOM: Object to the form. MS. GIULIANA: I withdraw that 10 question. Is the spread a concept that Dey 11 taught you? 12 MS. HANSCOM: Object to the form. 13 THE WITNESS: No. 14 BY MS. GIULIANA: 15 Did anyone ever tell you that there was Q. 16 anything wrong with talking about the spread 17 while you were at Dey? 18 Α. No. 19 Q. Or prior to your time at Dey? 20 Α. No. 21 MS. HANSCOM: Object to the form. 22 BY MS. GIULIANA:

# Charlotte, NC

November 11, 2008

299

- Q. Did you feel that there was anything
- wrong with talking about the spread while you
- 3 worked at Dey?
- 4 MS. HANSCOM: Object to the form.
- 5 THE WITNESS: No.
- 6 BY MS. GIULIANA:
- Q. And one definition of the spread is
- 8 that it's the difference between two price
- 9 points, correct?
- 10 A. Correct.
- MR. HENDERSON: Objection as to form.
- 12 BY MS. GIULIANA:
- Q. And the price points could be -- one of
- the price -- strike all that.
- And one of the price points on one hand
- could be AWP and on the other hand it could be a
- 17 contract price, correct?
- MS. HANSCOM: Object to the form.
- THE WITNESS: That's correct.
- 20 BY MS. GIULIANA:
- Q. And all those prices were well known to
- your customers, correct?

# Charlotte, NC

November 11, 2008

300

- MS. HANSCOM: Object to the form.
- THE WITNESS: They were visible to all,
- yes.
- 4 BY MS. GIULIANA:
- <sup>5</sup> Q. And a customer could get Dey's AWPs
- 6 from Red Book, correct?
- MS. HANSCOM: Object to the form.
- THE WITNESS: Yes.
- 9 BY MS. GIULIANA:
- 10 Q. Or First Data Bank?
- <sup>11</sup> A. Yes.
- MS. HANSCOM: Object to the form.
- 13 BY MS. GIULIANA:
- 0. Or from a wholesaler?
- MS. HANSCOM: Object to the form.
- THE WITNESS: Yes.
- 17 BY MS. GIULIANA:
- Q. Or from another publicly available
- 19 source?
- THE COURT REPORTER: I'm sorry, if you
- just pause for a minute so I can get her
- objection and then --

## Charlotte, NC

November 11, 2008

301

- MS. GIULIANA: I'm trying to get Mr.
- 2 Hill out before 5:15.
- THE COURT REPORTER: The last one I
- 4 have is or First Data Bank.
- 5 BY MS. GIULIANA:
- 6 Q. Or from a wholesaler?
- MS. HANSCOM: Object to the form.
- 8 BY MS. GIULIANA:
- 9 Q. Okay. So a customer could get Dey's
- 10 AWP from a wholesaler, correct?
- MS. HANSCOM: Object to the form.
- THE WITNESS: Yes.
- 13 BY MS. GIULIANA:
- Q. Or from another publicly available
- 15 source?
- MS. HANSCOM: Object to the form.
- THE WITNESS: Yes.
- 18 BY MS. GIULIANA:
- Q. And when you talked to customers while
- working at Dey, customers had a general awareness
- of the AWP of Dey's competitors, correct?
- MS. HANSCOM: Objection, form.

Henderson Legal Services, Inc.

202-220-4158

#### Charlotte, NC

November 11, 2008

302

- THE WITNESS: Yes.
- 2 BY MS. GIULIANA:
- Q. And your customers also knew what
- 4 contract price your competitors were offering to
- 5 those customers, correct?
- 6 MS. HANSCOM: Objection, form.
- 7 THE WITNESS: Yes.
- 8 BY MS. GIULIANA:
- 9 Q. Okay. So in any situation in which you
- may have discussed the spread with a customer,
- you weren't telling the customer something that
- they didn't already know, correct?
- MS. HANSCOM: Objection, form.
- THE WITNESS: That's correct.
- 15 BY MS. GIULIANA:
- Q. Or something that they didn't already
- have the ability to determine?
- MS. HANSCOM: Objection, form.
- THE WITNESS: That's correct.
- 20 BY MS. GIULIANA:
- Q. Or something that they weren't already
- <sup>22</sup> interested in?

Henderson Legal Services, Inc.

202-220-4158

#### Charlotte, NC

November 11, 2008

303

- MS. HANSCOM: Objection, form.
- THE WITNESS: Correct.
- 3 BY MS. GIULIANA:
- 4 O. Isn't it correct that in most of the
- 5 conversations that you had with customers
- 6 concerning the spread, it was the customer who
- initiated the topic?
- 8 MS. HANSCOM: Objection, form.
- 9 THE WITNESS: I would agree.
- 10 BY MS. GIULIANA:
- Q. Earlier today Mr. Henderson showed you
- 12 a document called a reimbursement comparison
- worksheet, correct?
- A. Yes.
- Q. Now, is there anything that would go
- into any of the blanks in that worksheet that a
- 17 customer didn't already know?
- MS. HANSCOM: Objection, form.
- THE WITNESS: No.
- 20 BY MS. GIULIANA:
- Q. So the customer already had the
- information available to fill in any of the

Henderson Legal Services, Inc.

202-220-4158

#### Charlotte, NC

```
304
1
    blanks in that worksheet?
2
               MS. HANSCOM: Objection, form.
3
               THE WITNESS: Yes, they would.
4
    BY MS. GIULIANA:
5
          Q.
               So in any situation where you sat down
6
    with a customer and reviewed that document with a
7
    customer, you are not telling the customer
8
    anything he didn't already know?
9
               MS. HANSCOM: Objection, form.
10
               THE WITNESS: No.
11
    BY MS. GTULTANA:
12
               And did you ever use the reimbursement
         Q.
13
    comparison worksheet with respect to Dey's
14
    Ipratropium product?
15
               MS. HANSCOM: Objection, form.
16
               THE WITNESS: No, I did not.
17
    BY MS. GIULIANA:
18
               Did you ever use the reimbursement
         Q.
19
    worksheet with respect to Dey's Cromolyn product?
20
               MS. HANSCOM: Objection, form.
21
               THE WITNESS: Not that I recall.
22
    BY MS. GIULIANA:
```

# November 11, 2008

#### Charlotte, NC

305

- Q. Did you ever use reimbursement
- 2 comparison worksheet or the concept set forth in
- that worksheet to try to convert a customer from
- a competitor's unit dose Albuterol product to
- Dey's unit dose Albuterol product?
- MS. HANSCOM: Objection, form.
- 7 THE WITNESS: Not on a unit dose to
- unit dose scenario, no.
- 9 BY MS. GIULIANA:
- Q. During the course of your work at Dey,
- did you have knowledge of the different
- 12 reimbursement formulas that different states used
- 13 to reimburse Medicaid claims?
- MS. HANSCOM: Objection, form.
- THE WITNESS: My knowledge was
- exclusive to Pennsylvania.
- MS. HANSCOM: I didn't hear that.
- THE WITNESS: My knowledge was
- exclusive to Pennsylvania, for the plans that
- were honored in Pennsylvania.
- 21 BY MS. GIULIANA:
- Q. And as far as you know, the decision as